CN117241817A - 包含环状肽化合物的制剂及其制备方法 - Google Patents

包含环状肽化合物的制剂及其制备方法 Download PDF

Info

Publication number
CN117241817A
CN117241817A CN202280029838.6A CN202280029838A CN117241817A CN 117241817 A CN117241817 A CN 117241817A CN 202280029838 A CN202280029838 A CN 202280029838A CN 117241817 A CN117241817 A CN 117241817A
Authority
CN
China
Prior art keywords
compound
composition
formulation
added
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280029838.6A
Other languages
English (en)
Chinese (zh)
Inventor
植户隆充
久保木友香理
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN117241817A publication Critical patent/CN117241817A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280029838.6A 2021-05-07 2022-05-06 包含环状肽化合物的制剂及其制备方法 Pending CN117241817A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-079015 2021-05-07
JP2021079015 2021-05-07
PCT/JP2022/019540 WO2022234850A1 (ja) 2021-05-07 2022-05-06 環状ペプチド化合物を含む製剤及びその製造方法

Publications (1)

Publication Number Publication Date
CN117241817A true CN117241817A (zh) 2023-12-15

Family

ID=83932759

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280029838.6A Pending CN117241817A (zh) 2021-05-07 2022-05-06 包含环状肽化合物的制剂及其制备方法

Country Status (12)

Country Link
US (1) US20240366711A1 (https=)
EP (1) EP4299069A4 (https=)
JP (2) JP7181442B1 (https=)
KR (2) KR20230169093A (https=)
CN (1) CN117241817A (https=)
AU (1) AU2022270498A1 (https=)
BR (1) BR112023019622A2 (https=)
CA (1) CA3219090A1 (https=)
IL (1) IL306018A (https=)
MX (1) MX2023013099A (https=)
TW (1) TW202308679A (https=)
WO (1) WO2022234850A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
PE20221323A1 (es) 2019-11-07 2022-09-09 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
TW202309065A (zh) 2021-05-07 2023-03-01 日商中外製藥股份有限公司 包含n-取代胺基酸殘基之環狀化合物的製造方法
CA3256645A1 (en) 2022-05-06 2025-04-23 Chugai Seiyaku Kabushiki Kaisha CYCLIC COMPOUND HAVING A SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS
EP4585605A1 (en) * 2022-10-20 2025-07-16 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide crystals
JPWO2024219480A1 (https=) * 2023-04-20 2024-10-24

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2501219A (en) * 2011-02-04 2013-10-16 Aegis Therapeutics Llc Orally bioavailable peptide drug compositions and methods thereof
JP6239979B2 (ja) 2011-03-04 2017-11-29 ニューヨーク・ユニバーシティ Ｒａｓの調節因子としての水素結合代替大環状分子
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
EP3881829A1 (en) 2014-11-07 2021-09-22 Sublimity Therapeutics Limited Compositions comprising cyclosporin
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
WO2018031730A2 (en) 2016-08-11 2018-02-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
JP7232758B2 (ja) 2017-06-09 2023-03-06 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ
WO2020122182A1 (ja) 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法
PE20221323A1 (es) * 2019-11-07 2022-09-09 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras
TW202309065A (zh) * 2021-05-07 2023-03-01 日商中外製藥股份有限公司 包含n-取代胺基酸殘基之環狀化合物的製造方法

Also Published As

Publication number Publication date
KR20230020548A (ko) 2023-02-10
KR20230169093A (ko) 2023-12-15
WO2022234850A1 (ja) 2022-11-10
IL306018A (en) 2023-11-01
EP4299069A4 (en) 2025-03-05
JP7181442B1 (ja) 2022-11-30
US20240366711A1 (en) 2024-11-07
EP4299069A1 (en) 2024-01-03
JP2023015334A (ja) 2023-01-31
CA3219090A1 (en) 2022-11-10
BR112023019622A2 (pt) 2023-11-14
AU2022270498A1 (en) 2023-10-05
TW202308679A (zh) 2023-03-01
MX2023013099A (es) 2023-11-17
JPWO2022234850A1 (https=) 2022-11-10
KR102582225B1 (ko) 2023-09-22

Similar Documents

Publication Publication Date Title
CN117241817A (zh) 包含环状肽化合物的制剂及其制备方法
TWI384984B (zh) 抗癌口服藥學組成物
EP2275419B1 (en) A lubiprostone crystal, its preparation process and its use
EP4031133B1 (en) Pyruvate kinase r (pkr) activating compositions
JP2019529568A (ja) キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
EA027869B1 (ru) Стабилизированная композиция такролимуса
EA039449B1 (ru) Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
CN103509001B (zh) 一种埃索美拉唑镁三水合物及其制备方法
WO2019149262A1 (zh) Sb-939的晶型及其制备方法和用途
HK40096081A (zh) 包含环状胜肽化合物的制剂及其制备方法
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
CN112933049B (zh) 含无定型态芳杂环化合物的组合物、其制备方法及用途
EA049912B1 (ru) Препарат, содержащий циклическое пептидное соединение, и способы его приготовления
CN116802183A (zh) 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
WO2021055863A1 (en) Pyruvate kinase r (pkr) activating compositions
TWI912013B (zh) 晶體、藥物組合物及其製備方法和應用
CN113372332B (zh) 一种奥希替尼新晶型
WO2019105359A1 (zh) Acalabrutinib的晶型及其制备方法和用途
HK40078162B (en) Pyruvate kinase r (pkr) activating compositions
HK40078162A (en) Pyruvate kinase r (pkr) activating compositions
WO2025240802A1 (en) Novel compositions, devices and methods
WO2019137027A1 (zh) Galunisertib的晶型及其制备方法和用途
CN121758503A (zh) 蛋白抑制剂或降解剂的酸式盐的晶型，其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096081

Country of ref document: HK